Leidos : Australia awarded Bureau of Meteorology Data Management support contract
March 06, 2020 at 11:32 am EST
Share
Canberra, Australia - Leidos Australia (NYSE:LDOS) has been awarded a contract by the Bureau of Meteorology (BOM) to deliver a Data Management Platform for the Bureau's ICT Transformation program.
The single-award contract has a three-year base period of performance, and a total approximate value of $16 million. Work commenced on the project in late November 2019.
The Bureau of Meteorology is Australia's national weather, climate and water agency. Its expertise and services assist Australians in dealing with the harsh realities of their natural environment, including drought, floods, fires, storms, tsunami and tropical cyclones. Through regular forecasts, warnings, monitoring and advice spanning the Australian region and Antarctic territory, the Bureau provides one of the most fundamental and widely used services of government.
Under the contract, Leidos Australia will deliver resilient services and reliable functionality via a secure, scalable and available Data Management Platform. The platform will be used to help meet the Bureau's information access needs, align the Data Governance and Information Life Cycle Management policies procedures and products, and will support the addition of emerging information capabilities.
'We are delighted to have signed our first contract with the Bureau of Meteorology,' said Leidos Australia Chief Executive, Christine Zeitz. 'The Australian community depends on the critical data that the Bureau collects and delivers and we look forward to supporting this through the platform.'
About Leidos
Leidos is a Fortune 500 information technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 36,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $11.09 billion for the fiscal year ended January 3, 2020. For more information, visit www.leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 3, 2020, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
Leidos Holdings, Inc. specializes in the provision of engineering, technological and scientific services. Net sales by business segment break down as follows:
- defense (56.6%): design, engineering and integration of technological solutions for intelligence, airborne surveillance and reconnaissance, maritime and land-based solutions, electronic warfare systems, and automated sensor, alarm, command and control systems, software development, cyber security solutions and data processing and analysis solutions, IT infrastructure development and integration, etc.;
- civil security (23.7%): development and integration of solutions for the protection of goods, data and digital information, solutions and systems for air traffic flow control and flight data management, vehicle and cargo inspection, explosives and radiation detection, computer security, environmental management, nuclear security, complex logistics management, etc.;
- health (19.7%): integration of complex systems and technological infrastructures for the management of data, medical information and electronic health records, provision of healthcare services, IT systems lifecycle management, research and development of biopharmaceuticals, etc.
Net sales by market are divided between the US Department of Defense and the intelligence community (49.4%), government agencies (37.4%) and commercial customers (13.2%).
The United States accounts for 91,4% of net sales.